FINWIRES · TerminalLIVE
FINWIRES

Research Alert: CFRA Maintains Strong Buy Rating On Shares Of Epam Systems, Inc.

By

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:

We cut our target from $231 to $184, 14x our 2026 EPS view, below EPAM's three-year average (19x) on AI competition risk. We raise our 2026 EPS view by $0.31 to $13.13 and 2027's by $0.23 to $14.53. Profitability continues to improve, supported by operational discipline and improved pricing in certain cases, which helps provide support to our view that EPAM is favorably positioned for more AI-focused projects. To this point, EPAM's AI revenues continue to grow solidly, up 19% Q/Q to $125M in Q1 for the fifth-straight double-digit sequential increase. Despite more bearish fears that the company's revenue deceleration (with its 2026 organic CC guide coming down to ~5.25% from ~6% prior), we see clear negative impacts from macro factors (i.e., the war in Iran) that should prove temporary, allowing for multiple expansion once these factors fade and AI deal momentum becomes more clear. Still, our lower target reflects heightened risks of perceived AI competition as impressive new AI models continue to roll out.

Related Articles

Research

Research Alert: CFRA Keeps Hold View On Shares Of Moderna; Shares +16% Amid Andes Outbreak

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:MRNA shares rose over 16% in five days following an Andes virus (rare hantavirus strain) outbreak on cruise ship MV Hondius. The vessel, carrying ~150 passengers from 23 countries, departed Argentina on April 1 and docked in the Canary Islands on May 10 with six confirmed cases, two probable cases, and three deaths. While no hantavirus vaccine currently exists, mRNA technology offers advantages including rapid development, strain adaptability, and stronger immune response versus traditional vaccines. Moderna is developing an mRNA hantavirus vaccine with Korea University, though the program remains in early preclinical stages (animal studies only), suggesting substantial time is needed despite current market enthusiasm. Health officials assess the pandemic risk as low given the virus requires close, prolonged contact for transmission. The Andes virus is the only known hantavirus strain to spread person-to-person. We raise our target to $58 from $48 based on NPV analysis, maintain our 2026 LPS at -$7.95, and keep 2027 LPS at -$4.82.

$MRNA
Research

Research Alert: CFRA Cuts Opinion On Shares Of Ingredion Incorporated To Hold From Buy

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We cut our 12-month target to $119 from $137, ~11x our 2026 EPS of $10.83 (cut from $11.43; 2027 EPS cut to $11.84 from $12.37) vs. the 13x long-term mean. Our revised outlook reflects ongoing challenges at the Argo facility, one of the company's largest manufacturing sites. In April 2026, this facility experienced its third major disruption in 18 months. While management has characterized these as separate incidents, the pattern suggests underlying operational issues. This latest disruption and associated costs prompted the company to lower its full-year EPS guidance. Additional headwinds include Mexican peso strength (costs are peso-denominated), rising energy prices, packaging inflation, tariffs, and concerns about indirect impacts on consumer demand in 2H 2026. Given the prolonged margin recovery in the F&II-U.S./Canada segment, we believe it is prudent to move to a Hold rating.

$INGR
Research

Research Alert: CFRA Reiterates Buy Opinion On Shares Of News Corp

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our 12-month target price by $2 to $31, 26x our FY 27 (Jun.) EPS estimate (unchanged multiple). We raise our FY 26 EPS estimate to $1.03 from $0.99 and FY 27's to $1.19 from $1.13. Following FQ3 (Mar-Q) results, we are reiterating our Buy opinion. We are encouraged by results at Dow Jones, where revenue growth is accelerating in its Risk & Compliance (+19% Y/Y) and Energy (+12% Y/Y) products. The Dow Jones segment also saw Wall Street Journal subscriptions reach 4.7M (+8% Y/Y) despite higher subscription prices, demonstrating pricing power. The company's Digital Real Estate Services grew revenue (+8% Y/Y ex-FX) despite new and existing home sales remaining in a slump. Adjusted EBITDA margins have expanded for eight consecutive quarters post-Foxtel spin-off, fueling improved free cash flow and accelerated buybacks. At 26x our FY 27 estimate vs. a 29x five-year average, shares trade at a discount with potential for re-rating as operational momentum continues.

$NWSA